Avenue Therapeutics Inc. (ATXI)
NASDAQ: ATXI
· Real-Time Price · USD
0.69
-0.06 (-8.00%)
At close: Oct 02, 2025, 3:12 PM
0.69
0.00%
After-hours: Oct 02, 2025, 03:12 PM EDT
Avenue Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1.4M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 1.4M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | 297K | -1.91M | -1.6M | -3.16M | -2.82M | -3.71M | -2.12M | -2.07M | -3.92M | -6.43M | -3.91M | -663K | -605K | -2.86M | -914K | -872K | -951K | -1M |
Interest Income | 31K | 32K | 24K | 51K | 52K | 49K | 22K | 9K | 57K | 37K | 16K | 1K | 1K | 2K | 1K | 1K | 2K | 3K |
Pretax Income | 329K | -1.85M | -1.51M | -3.09M | -2.7M | -4.35M | 617K | 513K | -4.02M | -7.6M | 524K | -662K | -604K | -2.86M | -913K | -871K | -949K | -998K |
Net Income | 335K | -1.85M | 2.95M | -3.08M | -7.19M | -4.34M | 640K | 526K | -4.01M | -7.54M | 575K | -662K | -604K | -2.86M | -913K | -871K | -949K | -998K |
Selling & General & Admin | 915K | 1.49M | 1.03M | 829K | 1.46M | 1.32M | 1.14M | 1.16M | 896K | 984K | 3.37M | 469K | 454K | 1.05M | 524K | 594K | 623K | 743K |
Research & Development | 192K | 411K | 565K | 2.33M | 1.36M | 2.39M | 982K | 907K | 3.03M | 5.45M | 545K | 194K | 151K | 1.81M | 390K | 278K | 328K | 258K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.11M | 1.91M | 1.6M | 3.16M | 2.82M | 3.71M | 2.12M | 2.07M | 3.92M | 6.43M | 3.91M | 663K | 605K | 2.86M | 914K | 872K | 951K | 1M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 332K | 1.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.11M | 1.91M | 1.6M | 3.16M | 2.82M | 3.71M | 2.12M | 2.07M | 3.92M | 6.43M | 3.91M | 663K | 605K | 2.86M | 914K | 872K | 951K | 1M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2.07K | n/a | n/a | n/a | -2K | -1K | -4K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 3.18M | 2.97M | 1.6M | 1.6M | 1.12M | 562.04K | 25.6M | 8.11M | 7.76M | 5.57M | 1.41M | 1.47M | 1.46M | 1.4M | 1.22M | 1.11M | 1.1M | 1.1M |
Shares Outstanding (Diluted) | 3.18M | 2.97M | 1.6M | 1.6M | 1.12M | 562.04K | 25.6M | 8.11M | 103.44K | 5.57M | 1.41M | 1.47M | 1.46M | 1.4M | 1.22M | 1.11M | 1.1M | 1.1M |
EPS (Basic) | 0.11 | -0.62 | 4.54 | -1.92 | -6.43 | -7.72 | 0.03 | 4.86 | -38.74 | -101.57 | 3.57 | -0.45 | -0.41 | -153.75 | -0.75 | -0.79 | -0.86 | -0.9 |
EPS (Diluted) | 0.11 | -0.62 | 4.54 | -1.92 | -6.43 | -7.72 | 0.03 | 4.86 | -38.74 | -101.57 | 3.57 | -0.45 | -0.41 | -153.75 | -0.75 | -0.79 | -0.86 | -0.9 |
EBITDA | 297K | -1.91M | -1.79M | -3.09M | -2.7M | -3.71M | 2.74M | 513K | -3.87M | -6.43M | 5.6M | -662K | -604K | -2.86M | -914K | -872K | -951K | -1M |
EBIT | 297K | -1.91M | -1.56M | -3.09M | -2.7M | -4.35M | 617K | 513K | -4.02M | -7.27M | 1.69M | -662K | -604K | -2.86M | -914K | -872K | -951K | -1M |
Depreciation & Amortization | n/a | n/a | -3.9M | 69K | 122K | 3.71M | 2.12M | n/a | 3.92M | 6.43M | 3.91M | 663K | 605K | 2.86M | 914K | 872K | 951K | 1M |